Marvel Biosciences Corp. is a biotechnology company dedicated to the discovery and development of synthetic chemical derivatives of established, proven drugs. Headquartered in Calgary, Canada, the company focuses on innovating within the healthcare sector by redeveloping off-patent pharmaceuticals to create novel therapeutics with enhanced efficacy and safety. Its lead asset, a fluorinated derivative of istradefylline, targets the adenosine A2a receptor—a pathway associated with diverse conditions such as Alzheimer’s disease, autism spectrum disorders, depression, anxiety, addiction, cancer, and non-alcoholic steatohepatitis. Marvel's approach emphasizes reducing both the cost and risk of drug development by modifying existing drugs, accelerating timelines to clinical readiness. The company is actively advancing its lead compound through preclinical studies and is preparing for regulatory milestones, including efforts to secure orphan drug designation for rare disorders like Rett Syndrome. By addressing significant unmet medical needs across large and growing markets, Marvel Biosciences is positioning itself as a transformative force in the development of next-generation therapeutics for neurological and non-neurological diseases.